Big pharma’s policy of mergers and swingeing cuts is having a devastating effect on drug research, says a former Pfizer …
Pharmaceutical industry leaders are increasingly admitting that the very low productivity of its R&D pipelines is unsustainable – but no …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

